2024
IN-HOSPITAL MORTALITY AMONG DEMENTIA PATIENTS IN CHINA: EVIDENCE FROM HOSPITAL ADMINISTRATIVE DATA
Lin Z, Ba F, Allore H, Chen X. IN-HOSPITAL MORTALITY AMONG DEMENTIA PATIENTS IN CHINA: EVIDENCE FROM HOSPITAL ADMINISTRATIVE DATA. Innovation In Aging 2024, 8: 955-956. PMCID: PMC11691659, DOI: 10.1093/geroni/igae098.3080.Peer-Reviewed Original ResearchDementia careIn-Hospital MortalityDementia patientsPrimary diagnosis of dementiaQuality dementia careAssociation of in-hospital mortalityOdds of in-hospital mortalityChinese older adultsDiagnosis of dementiaHospital-level factorsLower-level hospitalsInpatient medical recordsReduced in-hospital mortalityHigher-level counterpartsMultivariate logistic regressionHospital levelHospital characteristicsHospital transferOlder adultsWork statusAdmission typeInsurance typeAge bandsPatient levelDementiaIdentifying and optimizing psychosocial frailty in surgical practice
Schultz K, Richburg C, Park E, Leeds I. Identifying and optimizing psychosocial frailty in surgical practice. Seminars In Colon And Rectal Surgery 2024, 35: 101061. DOI: 10.1016/j.scrs.2024.101061.Peer-Reviewed Original ResearchPsychosocial frailtySocial risk profilePatient-reported dataPreoperative periodIncentivized screeningPsychological Well-BeingUnder-treatedPatient levelReimbursement strategiesFrailtyPostoperative complicationsSurgical outcomesIncreased riskWell-beingRisk profileBenefit patientsPatientsSurgical practiceContinuous care engagement in clinical practice: perspectives on selected current strategies for people with HIV in the United States
Villanueva M, Wheeler D, Applin S, Hodge T, Zack B, Rebeiro P. Continuous care engagement in clinical practice: perspectives on selected current strategies for people with HIV in the United States. Expert Review Of Anti-infective Therapy 2024, 22: 1043-1053. PMID: 39417530, DOI: 10.1080/14787210.2024.2412988.Peer-Reviewed Original ResearchCare engagementContinuing care engagementMultistakeholder groupHealthcare system levelPatient's support networkContinuous patient engagementHIV viral suppressionHIV-related morbidityAssociated with reduced ratesPatient engagementHIV carePersonal carePatient levelSupport networksMultidisciplinary teamCareDelivery researchEngagement strategiesGroup of expertsViral suppressionClinical practiceClinical levelAntiretroviral therapyHIVExternal partnershipsInternal Medicine Residents’ Confidence and Preferences in Hospital Medicine Competencies: A Multi-Site Study
Sankey C, Riquelme P, Windish D. Internal Medicine Residents’ Confidence and Preferences in Hospital Medicine Competencies: A Multi-Site Study. Journal Of General Internal Medicine 2024, 40: 70-81. PMID: 39384690, PMCID: PMC11780018, DOI: 10.1007/s11606-024-09111-z.Peer-Reviewed Original ResearchCommunity-based programsPoint-of-care ultrasoundAcademic medical centerCare transitionsPalliative careIM residentsClinical skillsResident confidenceInternal medicineCompetency domainsSenior residentsJunior residentsInternal medicine residentsIM residency programsSurvey-based assessmentSignificantly higher desireMedicine residentsResidency graduatesPGY-4 residentsPatient levelCareResidency programsMedical CenterSurvey responsesEducational gapDo sperm factors influence embryonic aneuploidy? Long live the oocyte
Fouks Y, Vaughan D, Sripada V, Penzias A, Bortoletto P, Sakkas D. Do sperm factors influence embryonic aneuploidy? Long live the oocyte. Human Reproduction 2024, 39: 2442-2452. PMID: 39352944, DOI: 10.1093/humrep/deae224.Peer-Reviewed Original ResearchImpact of male ageSperm qualityPloidy ratesPGT-AEmbryonic aneuploidyFrozen embryo transfer cyclesSperm-related factorsEmbryo transfer cyclesPGT-A cyclesPreimplantation genetic testingPropensity Score Matching AnalysisClinically significant interactionsRetrospective cohort studyMatching AnalysisScore matching analysisClinically relevant factorsSperm quality parametersPatient levelPatient-level analysisSemen quality parametersEffect of maternal ageAneuploid blastocystsEmbryo mosaicismSperm factorAneuploidy rateInternational equity in access to home dialysis
Iyengar A, Kalyesubula R, Darwish R, Luyckx V. International equity in access to home dialysis. Current Opinion In Nephrology & Hypertension 2024, 34: 112-120. PMID: 39282856, PMCID: PMC11608618, DOI: 10.1097/mnh.0000000000001027.Peer-Reviewed Original ResearchHome dialysisIn-centreMiddle-income countriesIn-centre haemodialysisDrivers of inequalityHealth systemLack of resourcesCommunity partnersPatient levelEquitable accessPeritoneal dialysisHomeHealthCliniciansGeopolitical levelNursesPatientsIn-centre dialysisAccessInequalityDoctorsLackDialysisReducing global inequalityCountriesSurgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis
Grubman D, Lansky A, Dwyer M, Zivadinov R, Pietras C, Nazif T, Moses J, Shah T, Gambone L, Leon M, Forrest J, Vora A, Parise H, Messé S. Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis. Cardiovascular Revascularization Medicine 2024, 65: 80. DOI: 10.1016/j.carrev.2024.04.179.Peer-Reviewed Original ResearchSurrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis
Gharzai L, Morris E, Suresh K, Nguyen-Tân P, Rosenthal D, Gillison M, Harari P, Garden A, Koyfman S, Caudell J, Jones C, Mitchell D, Krempl G, Ridge J, Gensheimer M, Bonner J, Filion E, Dunlap N, Stokes W, Le Q, Torres-Saavedra P, Mierzwa M, Schipper M. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis. The Lancet Oncology 2024, 25: 366-375. PMID: 38423050, PMCID: PMC10962533, DOI: 10.1016/s1470-2045(24)00016-0.Peer-Reviewed Original ResearchConceptsLocoregional progression-free survivalProgression-free survivalIntermediate clinical endpointsMetastasis-free survivalOverall survivalClinical endpointsOropharyngeal cancerComposite endpointIncidence of human papillomavirus (HPV)-related cancersP16-positive squamous cell carcinomaHuman papillomavirus (HPV)-related cancersP16-positive oropharyngeal cancerCancer treated with chemotherapyIndividual Patient Data Meta-AnalysisMedian Follow-UpPatient data meta-analysisSquamous-cell carcinomaSquamous cell carcinomaPatient levelClinical trial endpointsTreatment effectsData Meta-AnalysisLocoregional progressionNational Cancer InstituteDistant metastasis503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice
Wang Z, Martins B, Ardeleanu M, Yang M, Bégo-Le-Bagousse G, Sierka D, Strober B. 503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice. British Journal Of Dermatology 2024, 190: ii9-ii9. DOI: 10.1093/bjd/ljad498.011.Peer-Reviewed Original ResearchHealth statusIndividual patient levelTreatment satisfactionAtopic Dermatitis Control ToolPatient levelQuality of life of childrenObservational study of adultsAtopic dermatitisLongitudinal cohort studyPatient-reported outcomesPatient support programStudy of adultsQuality of lifeDupilumab treatmentMonth 1Lives of childrenBaseline surveyChronic inflammatory skin diseasePatients maintained responseSupport programsModerate-to-severe ADCohort studyLong-term treatmentInflammatory skin diseaseOutcome trajectories800.09 Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis
Grubman D, Lansky A, Dwyer M, Zivadinov R, Pietras C, Nazif T, Moses J, Shah T, Gambone L, Leon M, Forrest J, Vora A, Parise H, Messé S. 800.09 Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis. JACC Cardiovascular Interventions 2024, 17: s67-s68. DOI: 10.1016/j.jcin.2024.01.234.Peer-Reviewed Original Research
2023
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
Curigliano G, Dent R, Llombart-Cussac A, Pegram M, Pusztai L, Turner N, Viale G. Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer. Npj Breast Cancer 2023, 9: 56. PMID: 37380659, PMCID: PMC10307886, DOI: 10.1038/s41523-023-00560-z.Peer-Reviewed Original ResearchOptimal treatment pathwayBreast cancerCyclin D kinase 4/6 inhibitorDifferent adjuvant treatment modalitiesFuture risk stratification strategiesSimilar prognostic accuracyAdjuvant treatment modalitiesEarly breast cancerRisk of recurrenceRisk stratification strategiesRisk prediction toolsIndividual patient levelEpidermal growth factor receptorBreast cancer diagnosisGrowth factor receptorTreatment guidelinesRisk stratificationMultigene assaysTreatment modalitiesClinical trialsPatient levelPrognostic accuracyTreatment pathwaysEarly breast cancer diagnosisLevel IResearch Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop
Go A, Al-Khatib S, Desvigne-Nickens P, Bansal N, Bushnell C, Fang M, Freeman J, Gage B, Hanke T, Hylek E, Lopes R, Noseworthy P, Reddy V, Singer D, Thomas K, Hills M, Turakhia M, Zieman S, Cooper L, Benjamin E. Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Stroke 2023, 54: e75-e85. PMID: 36848427, PMCID: PMC9995163, DOI: 10.1161/strokeaha.121.038273.Peer-Reviewed Original ResearchConceptsAtrial fibrillationStroke preventionNational HeartRisk factorsPercutaneous left atrial appendage occlusionLeft atrial appendage occlusionStroke prevention therapyAF risk factorsStroke prevention strategiesRisk stratification toolAtrial appendage occlusionStrong risk factorIndividual patient levelOral anticoagulantsIschemic strokePrevention therapyAppendage occlusionStratification toolIntracranial hemorrhageLeading causeCardiovascular diseasePatient levelPrevention strategiesOptimal rolePrevention
2022
Assess the documentation of cognitive tests and biomarkers in electronic health records via natural language processing for Alzheimer’s disease and related dementias
Chen Z, Zhang H, Yang X, Wu S, He X, Xu J, Guo J, Prosperi M, Wang F, Xu H, Chen Y, Hu H, DeKosky S, Farrer M, Guo Y, Wu Y, Bian J. Assess the documentation of cognitive tests and biomarkers in electronic health records via natural language processing for Alzheimer’s disease and related dementias. International Journal Of Medical Informatics 2022, 170: 104973. PMID: 36577203, PMCID: PMC11325083, DOI: 10.1016/j.ijmedinf.2022.104973.Peer-Reviewed Original ResearchConceptsElectronic health recordsPatients' electronic health recordsCognitive testsCognitive test scoresFlorida health systemSeverity categoriesHealth recordsAD-related dementiaAD/ADRD researchAD/ADRDPatient levelAlzheimer's diseaseClinical narrativesHealth systemBiomarkersDifferent severityDiseaseSeverityPatientsADRD researchStandardized approachDementiaTest scoresPopulation characteristicsScoresSurrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer
Conforti F, Pala L, Bagnardi V, De Pas T, Colleoni M, Buyse M, Hortobagyi G, Gianni L, Winer E, Loibl S, Cortes J, Piccart M, Wolff AC, Viale G, Gelber RD. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer. JAMA Oncology 2022, 8: 1668-1675. PMID: 36201176, DOI: 10.1001/jamaoncol.2022.3755.Peer-Reviewed Original ResearchConceptsSurrogate end pointsPathologic complete responseEarly breast cancerBreast cancerEnd pointComplete responseClinical outcomesClinical benefitEvent-free survival dataLong-term patient outcomesReliable surrogate end pointsTrial levelPatient clinical benefitPatients' clinical outcomesAccelerated approval processNeoadjuvant RCTNeoadjuvant therapyPatient survivalClinical trialsDrug regulatory policyEffective therapyPathological responsePatient outcomesPatient levelDrug effectsTreatment patterns and medical costs of metastatic breast cancer care in the United States.
Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment patternsTreatment costsDiagnosis of MBCSocietal perspectiveHormone receptor statusBreast cancer careDays of diagnosisDe-identified databaseAverage wholesale priceElectronic health recordsMBC patientsMBC diagnosisReceptor statusCancer careInvasive cancerTriple NegativeClinical trialsReceptor subtypesPatient levelBreast cancerHuman epidermal growth factorPayer perspectiveDrug costsEpidermal growth factorDeep learning algorithm to predict pathologic complete response to neoadjuvant chemotherapy for breast cancer prior to treatment.
Choi R, Joel M, Hui M, Aneja S. Deep learning algorithm to predict pathologic complete response to neoadjuvant chemotherapy for breast cancer prior to treatment. Journal Of Clinical Oncology 2022, 40: 600-600. DOI: 10.1200/jco.2022.40.16_suppl.600.Peer-Reviewed Original ResearchPathologic complete responseNeoadjuvant chemotherapyBreast cancerComplete responseBreast MRIImproved disease-free survivalDisease-free survivalStage breast cancerPre-treatment predictionSubsets of ageNAC initiationOverall survivalPCR rateTreatment initiationUnnecessary toxicityTumor sizeSingle institutionDisease groupPatient levelPrognostic dataChemotherapyPatientsDiscordant predictionsCancerTotal test setMedication for opioid use disorder in the Arab World: A systematic review
Alawa J, Muhammad M, Kazemitabar M, Bromberg DJ, Garcia D, Khoshnood K, Ghandour L. Medication for opioid use disorder in the Arab World: A systematic review. International Journal Of Drug Policy 2022, 102: 103617. PMID: 35182841, PMCID: PMC9851143, DOI: 10.1016/j.drugpo.2022.103617.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersSystematic reviewGlobal public health concernOpioid agonist therapyImplementation science studyStandard of careCASP appraisal toolHealth system aspectsPublic health concernPositive health outcomesAgonist therapyOUD patientsPatients' qualityPatient satisfactionPatient levelInclusion criteriaPatient's perspectiveMOUDHealth outcomesFinal reviewMedicationsHealth concernHealth practitionersAddiction severity
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsInterobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group
Van Bockstal MR, Cooks M, Nederlof I, Brinkhuis M, Dutman A, Koopmans M, Kooreman L, van der Vegt B, Verhoog L, Vreuls C, Westenend P, Kok M, van Diest PJ, Nauwelaers I, Laudus N, Denkert C, Rimm D, Siziopikou KP, Ely S, Zardavas D, Roberts M, Floris G, Hartman J, Acs B, Peeters D, Bartlett JMS, Dequeker E, Salgado R, Giudici F, Michiels S, Horlings H, van Deurzen CHM. Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. Cancers 2021, 13: 4910. PMID: 34638394, PMCID: PMC8507620, DOI: 10.3390/cancers13194910.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesPD-L1 statusTNBC metastasisPrimary TNBCInterobserver agreementInternational Immuno-Oncology Biomarker Working GroupTriple-negative breast cancerBiomarker Working GroupBreast cancer benefitIndividual patient levelChance of treatmentCancer benefitDistant metastasisMetastatic TNBCImmune cellsSame pathologistPatient levelBreast cancerAnatomic localizationConsensus diagnosisMetastatic specimensMetastasisInter-pathologist agreementTNBCModerate agreement
2019
The Evolving Landscape of Impella® Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention with Mechanical Circulatory Support
Amin AP, Spertus JA, Curtis JP, Desai N, Masoudi FA, Bach RG, McNeely C, Al-Badarin F, House JA, Kulkarni H, Rao SV. The Evolving Landscape of Impella® Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention with Mechanical Circulatory Support. Circulation 2019, 141: 273-284. PMID: 31735078, DOI: 10.1161/circulationaha.119.044007.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionMechanical circulatory supportAcute kidney injuryImpella useOdds ratioKidney injuryCoronary interventionClinical outcomesCirculatory supportAdverse outcomesPremier Healthcare DatabaseClustering of patientsHigh rateAdverse eventsPatient levelImpellaPropensity adjustmentHospital levelHealthcare databasesPatientsUS hospitalsHospitalPropensity scoreAssociated outcomesWide variation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply